SLC5A2 and hydrops fetalis: Recent population-level data demonstrate that patients from lower-income or structurally marginalized backgrounds face significant treatment gaps, underscoring the need for health-system and policy-level strategies to ensure equitable implementation of SGLT2 inhibitor therapy in HF [33].